Since the first U.S. reported case of human immunodeficiency virus in 1981, the scientific community has not wavered in its commitment to both extending the life expectancy and improving the quality ...
In a first, the study published in the journal Emerging Microbes and Infections demonstrated the team’s patented therapeutic candidate, an HIV-virus-like-particle (HLP), is 100 times more effective ...
CHICAGO (Reuters) - The AIDS virus is especially hard to fight because few people develop antibodies to neutralize it, but U.S. researchers said on Thursday they have found an immunity gene that may ...
The human immunodeficiency virus (HIV) is a retrovirus that integrates into the human genome. This intact, integrated genome is referred to as a provirus and represents a latent or dormant form of the ...
Since the first reported cases in 1981, the human immunodeficiency virus (HIV) infected approximately 86 million people and resulted in the deaths of tens of millions of people from acquired ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
ATLANTA, GA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire-- GeoVax Labs, Inc. (GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
S.J.D. Neil et al., “Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu,” Nature 451:425–30, 2008. (Cited in 96 papers) To be released from some cells, HIV-1 requires an accessory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results